Clinical Trial Update: Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) [Phase 1]

View source ↗

Summary

Emory University conducted a Phase 1 trial evaluating rifaximin to prevent acute graft-versus-host disease in patients undergoing bone marrow transplantation fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Graft-versus-host Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Emory University | Conditions: Malignancy, Bone Marrow Transplantation | Phase 1 | Status: COMPLETED